Johnson & Johnson reported strong Q1 2026 results with revenue up 9.9% year-over-year to $24.06 billion, driven by growth in innovative medicines and MedTech. The company raised its quarterly dividend by 3.1%, marking 64 consecutive years of increases, supported by a robust AAA credit rating and strong cash flow. Management also raised full-year revenue and earnings guidance, highlighting the company's resilience due to non-cyclical healthcare demand and diversified product portfolio. While it may lag in speculative bull markets, Johnson & Johnson remains a durable, income-generating investment with steady growth prospects.
The investor highlights NVIDIA's massive revenue growth and cash flow, boosted by AI demand and strong capital returns. Eli Lilly impresses with high revenue growth driven by key drugs like Mounjaro and Foundayo, despite pricing pressures. Johnson & ...
Johnson & Johnson's stock has risen 13.73% year-to-date, driven by strong oncology sales and MedTech performance. Despite a recent earnings dip due to litigation costs and biosimilar competition, the company remains optimistic about accelerated growt...
The AAM S&P 500 High Dividend Value ETF (SPDV) selects high-yield, value-driven stocks from the S&P 500 while limiting sector concentration to ensure diversification. Its top holdings include financially strong companies like Johnson & Johnson, Micro...
Major S&P 500 companies like Johnson & Johnson, Procter & Gamble, Target, Ingersoll Rand, and Apple are significantly increasing dividends and share buybacks in 2026. Johnson & Johnson extended its dividend streak to 64 years, Procter & Gamble to 70 ...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
